Business
After years of contraction, investors see biotech reentering a growth cycle driven by scientific progress, asset quality and renewed conviction in oncology, obesity and neuroscience innovation.
FEATURED STORIES
With the biopharma industry performing better of late, analysts, executives and other industry watchers are “cautiously optimistic”—a term heard all over the streets of San Francisco at the J.P. Morgan Healthcare Conference earlier this month.
Attendance at the Biotech CEO Sisterhood’s annual photo of women leaders and allies in Union Square doubled this year. There’s still more work to do.
After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will capture the lion’s share of the market for on-demand use.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Lumen Biosciences closed a $16 million Series B funding round that will support the development of its three clinical programs aimed at C. difficile, norovirus and traveler’s diarrhea.
When Bionano Genomics acquired Lineagen, Inc. in August, the genomic analysis company gained the final piece it needed to provide comprehensive structural variation detection for researchers and drug developers and a reimbursement pathway for clinicians who want to use its technology to replace cytogenetic tests to diagnose cancers and rare diseases.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 31, 2020.
On Sunday, U.S. Food and Drug Administration Commissioner Stephen Hahn told the Financial Times that he would potentially fast-track a COVID-19 vaccine before clinical trials are done if it was “appropriate.”
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 28, 2020.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
President Donald Trump pledged a vaccine for the novel coronavirus that causes COVID-19 would be available by the end of the year. The remarks were made during an acceptance speech for the Republican Party presidential nomination Thursday night.
When someone gets sick with COVID-19, there is a lag in an efficient immune response, giving the virus time to do significant damage before the immune system can reign in the infection.
New investors who joined the funding round include Viking Global Investors, Venrock Healthcare Capital Partners and Janus Henderson Investors.
The idea is to support companies that anticipate “potential health security threats, activating the global innovation community, and amplifying scientific and technological advances with the aim to prepare for and respond to our rapidly evolving global health environment.”